Staphylococcus Capitus Blebitis Following Preserflo MicroShunt Implantation.

Area of Science:

• Ophthalmology
• Glaucoma Surgery
• Infectious Disease

Background:

• Glaucoma is a leading cause of irreversible blindness.
• Minimally invasive glaucoma surgery (MIGS) like PRESERFLO® MicroShunt implantation offers an alternative to traditional procedures.
• Complications, though rare, require careful monitoring and management.

Purpose of the Study:

• To document a case of early-onset blebitis following PRESERFLO® MicroShunt implantation.
• To highlight the clinical presentation and management of this rare complication.

Main Methods:

• A case report detailing a 73-year-old woman with pseudoexfoliative glaucoma.
• The patient underwent PRESERFLO® MicroShunt implantation with mitomycin C.
• Clinical examination, microbiological cultures, and surgical intervention were performed.

Main Results:

• The patient developed symptoms of blebitis three months post-surgery, including pain and decreased visual acuity.
• Infectious blebitis was confirmed by Staphylococcus capitis isolation from cultures.
• Surgical explantation of the microshunt and antibiotic therapy successfully restored intraocular pressure and visual function.

Conclusions:

• Blebitis is a potential, albeit rare, complication associated with PRESERFLO® MicroShunt implantation.
• Prompt diagnosis and intervention, including device explantation, are crucial to prevent the spread of infection and preserve vision.